S 16020-2

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H585118

CAS#: 178169-99-8

Description: S 16020-2 is an olivacine derivative, and DNA topoisomerase II inhibitor endowed with a remarkable antitumor activity against various experimental tumors.

Chemical Structure

img
S 16020-2
CAS# 178169-99-8
Instruction

Theoretical Analysis

Hodoodo Cat#: H585118
Name: S 16020-2
CAS#: 178169-99-8
Chemical Formula: C22H26Cl2N4O2
Exact Mass: 448.14
Molecular Weight: 449.376
Elemental Analysis: C, 58.80; H, 5.83; Cl, 15.78; N, 12.47; O, 7.12

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: S 16020-2; S16020-2; S-16020-2

IUPAC/Chemical Name: 6H-Pyrido(4,3-b)carbazole-1-carboxamide, N-(2-(dimethylamino)ethyl)-9-hydroxy-5,6-dimethyl-, dihydrochloride

InChi Key: DSJBVXJNKBKZSB-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H24N4O2.2ClH/c1-13-15-7-8-23-20(22(28)24-9-10-25(2)3)17(15)12-18-16-11-14(27)5-6-19(16)26(4)21(13)18;;/h5-8,11-12,27H,9-10H2,1-4H3,(H,24,28);2*1H

SMILES Code: O=C(C1=NC=CC2=C(C)C(N(C)C3=C4C=C(O)C=C3)=C4C=C21)NCCN(C)C.[H]Cl.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 449.38 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Guillonneau C, Nault A, Raimbaud E, Léonce S, Kraus-Berthier L, Pierré A, Goldstein S. Cytotoxic and antitumoral properties in a series of new, ring D modified, olivacine analogues. Bioorg Med Chem. 2005 Jan 3;13(1):175-84. PubMed PMID: 15582462.

2: Pichard-Garcia L, Weaver RJ, Eckett N, Scarfe G, Fabre JM, Lucas C, Maurel P. The olivacine derivative s 16020 (9-hydroxy-5,6-dimethyl-N-[2-(dimethylamino)ethyl)-6H-pyrido(4,3-B)-carbazole-1-c arboxamide) induces CYP1A and its own metabolism in human hepatocytes in primary culture. Drug Metab Dispos. 2004 Jan;32(1):80-8. PubMed PMID: 14709624.

3: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 May;25(4):317-40. PubMed PMID: 12808477.

4: Kraus-Berthier L, Guilbaud N, Léonce S, Parker T, Genissel P, Guillonneau C, Goldstein S, Atassi G, Pierré A. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug. Cancer Chemother Pharmacol. 2002 Aug;50(2):95-103. Epub 2002 Jun 25. PubMed PMID: 12172972.

5: Le Mée S, Chaminade F, Delaporte C, Markovits J, Saucier JM, Jacquemin-Sablon A. Cellular resistance to the antitumor DNA topoisomerase II inhibitor S16020-2: importance of the N-[2(Dimethylamino)ethyl]carbamoyl side chain. Mol Pharmacol. 2000 Oct;58(4):709-18. PubMed PMID: 10999940.

6: Malonne H, Farinelle S, Decaestecker C, Gordower L, Fontaine J, Chaminade F, Saucier JM, Atassi G, Kiss R. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1. Clin Cancer Res. 2000 Sep;6(9):3774-82. PubMed PMID: 10999772.

7: Soudon J, Milano G, Poullain MG, Fischel JL, Formento P, Berlion M, Giroux B. Time-schedule dependency of S 16020, a new topoisomerase II inhibitor. Anticancer Drugs. 1999 Jul;10(6):597-604. PubMed PMID: 10885908.

8: Kraus-Berthier L, Jan M, Guilbaud N, Naze M, Pierré A, Atassi G. Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice. Clin Cancer Res. 2000 Jan;6(1):297-304. PubMed PMID: 10656461.

9: Guillonneau C, PierréA, Charton Y, Guilbaud N, Kraus-Berthier L, Léonce S, Michel A, Bisagni E, Atassi G. Synthesis of 9-O-substituted derivatives of 9-hydroxy-5, 6-dimethyl-6H-pyrido[4,3-b]carbazole-1-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10- and 11-methyl analogues with improved antitumor activity. J Med Chem. 1999 Jun 17;42(12):2191-203. PubMed PMID: 10377224.

10: Pierré A, Léonce S, Pérez V, Atassi G. Circumvention of P-glycoprotein-mediated multidrug resistance by S16020-2: kinetics of uptake and efflux in sensitive and resistant cell lines. Cancer Chemother Pharmacol. 1998;42(6):454-60. PubMed PMID: 9788571.

11: Le Mée S, Pierré A, Markovits J, Atassi G, Jacquemin-Sablon A, Saucier JM. S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol Pharmacol. 1998 Feb;53(2):213-20. PubMed PMID: 9463478.

12: Kraus-Berthier L, Guilbaud N, Jan M, Saint-Dizier D, Rouillon MH, Burbridge MF, Pierré A, Atassi G. Experimental antitumour activity of S 16020-2 in a panel of human tumours. Eur J Cancer. 1997 Oct;33(11):1881-7. PubMed PMID: 9470851.

13: Malonne H, Atassi G. DNA topoisomerase targeting drugs: mechanisms of action and perspectives. Anticancer Drugs. 1997 Oct;8(9):811-22. Review. PubMed PMID: 9402307.

14: Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Pierré A, Atassi G. Antitumor activity of S 16020-2 in two orthotopic models of lung cancer. Anticancer Drugs. 1997 Mar;8(3):276-82. PubMed PMID: 9095333.

15: Léonce S, Perez V, Casabianca-Pignede MR, Anstett M, Bisagni E, Pierré A, Atassi G. In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs. 1996;14(2):169-80. PubMed PMID: 8913838.

16: Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M, Visalli M, Bisagni E, Pierré A, Atassi G. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother Pharmacol. 1996;38(6):513-21. PubMed PMID: 8823492.